Novartis' pelacarsen fails Lp(a)HORIZON, the third major CV outcomes trial miss in two months, as Amgen, Lilly and others push ahead.
After Novo Nordisk and AstraZeneca, Novartis is the third big pharma to suffer a major cardiovascular outcomes trial failure in the past two months.
The …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or…
Novartis' del-desiran misses HARBOR trial's primary endpoint, adding to pelacarsen miss and CAR-T deaths; shares sink 10%.
(Bloomberg) -- A Novartis AG drug billed as a potential blockbuster failed to reduce the risk of heart attacks and strokes in a…
Medical specialists are reeling after experimental medication did not pass a massive clinical trial, upending hopes for a new era…
Novartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and…
Novartis plans Phase 3 trial of pacibekitug for CV risk reduction despite Novo Nordisk's failed ZEUS trial of ziltivekimab.…
Another heart drug fails, shocking cardiologists
